Globe Newswire (Thu, 2-Jul 9:05 AM ET)
Globe Newswire (Tue, 23-Jun 9:05 AM ET)
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
Globe Newswire (Tue, 2-Jun 9:05 AM ET)
Globe Newswire (Wed, 27-May 9:05 AM ET)
Globe Newswire (Tue, 26-May 4:05 PM ET)
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Globe Newswire (Fri, 15-May 11:00 AM ET)
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Globe Newswire (Thu, 7-May 4:05 PM ET)
Globe Newswire (Tue, 5-May 4:05 PM ET)
Globe Newswire (Thu, 30-Apr 9:05 AM ET)
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
Globe Newswire (Tue, 28-Apr 4:05 PM ET)
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Myriad Genetics trades on the NASDAQ stock market under the symbol MYGN.
As of July 8, 2026, MYGN stock price declined to $5.76 with 87,254 million shares trading.
MYGN has a beta of 1.56, meaning it tends to be more sensitive to market movements. MYGN has a correlation of 0.05 to the broad based SPY ETF.
MYGN has a market cap of $543.99 million. This is considered a Small Cap stock.
Last quarter Myriad Genetics reported $200 million in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .
In the last 3 years, MYGN traded as high as $29.30 and as low as $3.53.
The top ETF exchange traded funds that MYGN belongs to (by Net Assets): XBI, IWM, VTI, IWN, VXF.
MYGN has underperformed the market in the last year with a return of +8.9%, while SPY returned +21.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MYGN shares. However, MYGN has outperformed the market in the last 3 month and 2 week periods, returning +21.5% and +24.4%, while SPY returned +13.2% and +1.5%, respectively. This indicates MYGN has been having a stronger performance recently.
MYGN support price is $5.59 and resistance is $6.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MYGN shares will trade within this expected range on the day.
